Loading organizations...
Raziel Therapeutics develops RZL-012, a proprietary injectable compound for focal fat reduction. This non-surgical treatment selectively disrupts adipocyte membranes, leading to controlled fat cell elimination in a single session. The company advances applications for aesthetic concerns like submental fat and therapeutic indications such as Dercum's disease, establishing a targeted approach for various body contouring needs.
Established in 2012, Raziel Therapeutics was co-founded by Alon Bloomenfeld, who serves as CEO. Bloomenfeld leveraged his executive experience in finance and management within the biotech sector. The foundational insight centered on addressing the demand for an effective, non-surgical intervention for localized fat deposits.
The company's product serves individuals seeking aesthetic body contouring and those with medical conditions involving abnormal fat accumulation. Raziel's vision is to broaden RZL-012’s utility as a versatile platform for non-surgical fat reduction, offering a minimally invasive alternative to traditional surgical procedures.
Raziel Therapeutics has raised $22.0M across 1 funding round.
Raziel Therapeutics has raised $22.0M in total across 1 funding round.
Raziel Therapeutics is a clinical-stage pharmaceutical company developing RZL-012, a proprietary fat-dissolving injectable compound for non-surgical, targeted fat reduction.[1][2][3] It targets aesthetic applications like submental fat reduction and body contouring, as well as therapeutic uses such as Dercum's Disease, serving patients and clinicians seeking minimally invasive alternatives to surgery amid rising obesity prevalence linked to diseases like diabetes and heart disease.[1][3] The company operates a clinical pipeline from Phase 1 to Phase 3, including FDA trials, with a licensing deal for China via Fosun Pharma, and shows growth through $22 million in Series C funding, positioning it in the expanding medical aesthetics and obesity treatment markets.[1][2][3]
Founded in 2012 in Rehovot, Israel, Raziel Therapeutics emerged to address the need for non-surgical fat reduction solutions, leveraging Israel's strong healthcare R&D ecosystem.[1][3] Key leaders include CEO Alon Bloomenfeld, with prior drug development expertise; Dr. Schaison, former Allergan executive who scaled Botox businesses; Eran, ex-Teva Pharmaceuticals head of CNS/Pain projects; and Racheli, Ph.D. from Weizmann Institute with clinical R&D experience.[3] Early milestones include developing RZL-012, signing a commercial license with Fosun Pharma for China, and advancing trials, including a 2021 Dermatologic Surgery publication on Dercum’s Disease testing.[3]
Raziel rides the obesity and medical aesthetics megatrend, where diagnosed cases surged (U.S. at ~61-66% of cases in 2023), driving demand for non-invasive fat reduction amid links to diabetes, heart disease, and cancer.[1] Timing aligns with Big Pharma shifts—like Eli Lilly's retatrutide success (17.5% weight loss in Phase II) and Pfizer's lotiglipron halt—creating space for localized therapies over systemic drugs.[1] Israel's biotech hub amplifies this via R&D investment and collaborations, while Raziel influences the ecosystem by pioneering injectables that could expand aesthetics markets and therapeutic options for rare fat disorders.[1][3]
Raziel is poised for Phase 3 readouts and potential approvals, with China commercialization via Fosun accelerating revenue amid obesity drug momentum.[1][3] Trends like non-surgical aesthetics growth and precision therapeutics will propel it, potentially evolving its role from innovator to market leader if RZL-012 demonstrates durable efficacy. Watch for U.S. FDA milestones and partnerships to scale beyond focal fat, reinforcing its edge in a $multi-billion pipeline-rich sector.[1][2]
Raziel Therapeutics has raised $22.0M in total across 1 funding round.
Raziel Therapeutics's investors include Pontifax, Catalyst Fund, Docor International Management, Peregrine Investments, Karimah Es Sabar, Wille Finance.
Raziel Therapeutics has raised $22.0M across 1 funding round. Most recently, it raised $22.0M Series C in December 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2019 | $22.0M Series C | Pontifax | Catalyst Fund, Docor International Management, Peregrine Investments, Karimah Es Sabar, Wille Finance |